Jamjoom Pharmaceuticals Factory Company SJSC banner
J

Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015

Watchlist Manager
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Watchlist
Price: 156 SAR 4.7% Market Closed
Market Cap: ﷼10.9B

EV/GP

11.3
Current
6%
Cheaper
vs 3-y average of 12

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
11.3
=
Enterprise Value
﷼10.6B
/
Gross Profit
﷼938.8m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
11.3
=
Enterprise Value
﷼10.6B
/
Gross Profit
﷼938.8m

Valuation Scenarios

Jamjoom Pharmaceuticals Factory Company SJSC is trading below its 3-year average

If EV/GP returns to its 3-Year Average (12), the stock would be worth ﷼165.89 (6% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-23%
Maximum Upside
+9%
Average Downside
0%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 11.3 ﷼156
0%
3-Year Average 12 ﷼165.89
+6%
5-Year Average 12 ﷼165.89
+6%
Industry Average 8.7 ﷼120.85
-23%
Country Average 12.3 ﷼169.84
+9%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
SA
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
10.9B SAR 11.3 23.5
US
Eli Lilly and Co
NYSE:LLY
883B USD 17.4 44.1
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.3 16.6

Market Distribution

In line with most companies in Saudi Arabia
Percentile
45th
Based on 208 companies
45th percentile
11.3
Low
2.4 — 8.4
Typical Range
8.4 — 16.3
High
16.3 —
Distribution Statistics
Saudi Arabia
Min 2.4
30th Percentile 8.4
Median 12.3
70th Percentile 16.3
Max 315.2

Jamjoom Pharmaceuticals Factory Company SJSC
Glance View

Market Cap
10.9B SAR
Industry
Pharmaceuticals

Jamjoom Pharmaceuticals Factory Company SJSC, nestled in the heart of Saudi Arabia, has emerged as a formidable player in the Middle East's pharmaceutical landscape. Founded in 1994, the company was borne out of a vision to cater to the growing healthcare demands of the region, leveraging both high-tech manufacturing and rigorous scientific research. Initially focused on generic medications, Jamjoom Pharmaceuticals has since expanded its portfolio to include a diverse range of products from ophthalmology to dermatology. With a state-of-the-art manufacturing facility in Jeddah, it integrates advanced technologies into its processes, ensuring that its products meet global quality standards. The company's adherence to Good Manufacturing Practices (GMP) and its drive to innovate are reflected in its collaborations with international partners for research and development, exemplifying its commitment to producing affordable, high-quality medications. At the core of Jamjoom Pharmaceuticals' business model is a robust distribution network that spans across the Middle East and North Africa (MENA) region, facilitating seamless supply chain operations. Revenue is generated primarily through the sale of its diversified product line, which includes prescription medications, over-the-counter solutions, and specialized healthcare products. The company leverages relationships with hospitals, healthcare providers, and retail pharmacies to enhance its market penetration. Its strategic focus on emerging therapeutic areas and persistent efforts to expand its international presence are paying dividends as it grows its footprint beyond the MENA region. By consistently reinvesting in research and development, Jamjoom Pharmaceuticals keeps its pipeline replenished with innovations that not only promise to enhance patient outcomes but also ensure sustainable profitability in a competitive pharmaceutical market.

Intrinsic Value
113.67 SAR
Overvaluation 27%
Intrinsic Value
Price ﷼156
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett